
CNSide Diagnostics Expands CNSide Assay Platform to California

Plus Therapeutics’ Subsidiary CNSide Diagnostics Expands CNSide Assay Platform to California Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9600305) on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

